Free Trial

Zenas BioPharma (ZBIO) Stock Price, News & Analysis

Zenas BioPharma logo
$15.42 -0.90 (-5.51%)
As of 02:22 PM Eastern

About Zenas BioPharma Stock (NASDAQ:ZBIO)

Key Stats

Today's Range
$15.14
$16.50
50-Day Range
$9.14
$16.32
52-Week Range
$5.83
$26.25
Volume
96,852 shs
Average Volume
185,516 shs
Market Capitalization
$645.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.67
Consensus Rating
Buy

Company Overview

Zenas BioPharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
35th Percentile Overall Score

ZBIO MarketRank™: 

Zenas BioPharma scored higher than 35% of companies evaluated by MarketBeat, and ranked 745th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Zenas BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Zenas BioPharma has only been the subject of 2 research reports in the past 90 days.

  • Read more about Zenas BioPharma's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Zenas BioPharma is -4.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Zenas BioPharma is -4.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Zenas BioPharma has a P/B Ratio of 2.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Zenas BioPharma's valuation and earnings.
  • Short Interest

    There is no current short interest data available for ZBIO.
  • Short Interest

    There is no current short interest data available for ZBIO.
  • News Sentiment

    Zenas BioPharma has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.06 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Zenas BioPharma this week, compared to 11 articles on an average week.
  • Search Interest

    Only 1 people have searched for ZBIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Zenas BioPharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.50% of the stock of Zenas BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Zenas BioPharma's insider trading history.
Receive ZBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zenas BioPharma and its competitors with MarketBeat's FREE daily newsletter.

ZBIO Stock News Headlines

Invest where Wall Street isn’t looking—yet
Some investors quietly turn a few thousand dollars into hundreds of thousands—before a company ever goes public. Sure… some of that is luck. But it’s not dumb luck. It’s knowing where to look, and even more importantly, which deals to avoid.
See More Headlines

ZBIO Stock Analysis - Frequently Asked Questions

Zenas BioPharma's stock was trading at $7.90 at the start of the year. Since then, ZBIO shares have increased by 95.2% and is now trading at $15.42.

Zenas BioPharma, Inc. (NASDAQ:ZBIO) issued its quarterly earnings data on Thursday, May, 15th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.35. The firm earned $10 million during the quarter, compared to the consensus estimate of $5 million.

Zenas BioPharma (ZBIO) raised $225 million in an initial public offering on Friday, September 13th 2024. The company issued 13,235,294 shares at $17.00 per share.

Shares of ZBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zenas BioPharma investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Trade Desk (TTD), Advanced Micro Devices (AMD), Biosig Technologies (BSGM), Ford Motor (F) and Genius Sports (GENI).

Company Calendar

Last Earnings
5/15/2025
Today
7/25/2025
Next Earnings (Estimated)
8/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ZBIO
Previous Symbol
NASDAQ:ZBIO
CIK
1953926
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

High Price Target
$45.00
Low Price Target
$30.00
Potential Upside/Downside
+124.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.47
Quick Ratio
6.47

Sales & Book Value

Annual Sales
$15 million
Price / Sales
45.52
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.48 per share
Price / Book
2.18

Miscellaneous

Outstanding Shares
41,834,000
Free Float
34,931,000
Market Cap
$682.73 million
Optionable
N/A
Beta
N/A

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:ZBIO) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners